-
Real-World Pharmacovigilance of Metoprolol: A Disproportionality Analysis of Adverse Events Using US FDA Adverse Event Reporting System (FAERS) and Bioinformatics
Sep 9, 2025, 16:22 PM -
Sex Differences in Autoimmune Multimorbidity Across 11 Autoimmune Disorders in the Real-World Setting in Germany
Sep 9, 2025, 16:22 PM -
Primary Expenditure Drivers and Future Challenges From Emerging Technologies in Brazilian Private Market Real-World Data Analysis From a Brazilian Employer-Sponsored, Self-Insured Health Plan
Sep 9, 2025, 16:22 PM -
The IMPACT Framework: A Value Assessment Framework for Holistic Health Technology Assessment
Sep 9, 2025, 16:22 PM -
Trends of Prescriptions for Medical Technologies Not Covered by the Colombian Health Benefits Package Between 2020 and 2024: A Descriptive Study
Sep 9, 2025, 16:22 PM -
Conceptualizing an Economic Model Structure for Parkinson's Disease
Sep 9, 2025, 16:22 PM -
A Comparison of the NICE HST Program With Health Technology Assessments of Ultra-Orphan Drugs From France and Germany
Sep 9, 2025, 16:22 PM -
Organizational Budget Impact Analysis of the Port-Delivery Platform With SUSVIMO in Age-Related Macular Degeneration (AMD) in France
Sep 9, 2025, 16:22 PM -
Socioeconomic and Geographic Inequalities in Colorectal Cancer Care Utilization and Expenditures: A Decomposition Analysis
Sep 9, 2025, 16:22 PM -
Insights From a French Postmarketing Authorization Early Access (MA EA) Mechanism: Projecting Clinical and Economic Benefits of Neoadjuvant Nivolumab–Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer
Sep 9, 2025, 16:22 PM -
Orphan Drugs Availability in Israel: A Base for Policy Development
Sep 9, 2025, 16:22 PM -
Can Generative AI Deliver Patient-Friendly Summaries? A Case Study Using NICE Guidance for Spinal Muscular Atrophy
Sep 9, 2025, 16:22 PM -
Budget Impact of Implementing a Case-Finding Program in UK Patients at High Risk for COPD to Explore Cost Savings Due to Earlier Diagnosis
Sep 9, 2025, 16:22 PM -
Cost Analysis of Polatuzumab Vedotin in Combination With Rituximab Cyclophosphamide Doxorubicin and Prednisone in the Treatment of Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma in Portugal
Sep 9, 2025, 16:22 PM -
Economic Burden of Progressive Pulmonary Fibrosis (PPF) in the Brazilian Private Healthcare System
Sep 9, 2025, 16:22 PM -
Oracle Real-World Data: Analysis of the Characteristics and Representativeness of Oracle's Linked EHR-Claims Database
Sep 9, 2025, 16:22 PM -
Level of ICER of Health Economic Assessment in France in 2024
Sep 9, 2025, 16:22 PM -
Patient-Reported Stigma Across Health Conditions: Insights From the National Health and Wellness Survey (NHWS) in China
Sep 9, 2025, 16:22 PM -
Mind the Gap: Understanding the Global Imbalances in Spending for Innovative Medicines
Sep 9, 2025, 16:22 PM -
The Reliability and Validity of the Greek Version of the Pediatric Quality of Life Inventory™ 30 Duchenne Muscular Dystrophy Module in Children With Duchenne Muscular Dystrophy
Sep 9, 2025, 16:22 PM
